Crinetics Pharmaceuticals (NASDAQ:CRNX) Stock Acquired Rep. Gilbert Ray Cisneros, Jr.

Representative Gilbert Ray Cisneros, Jr. (Democratic-California) recently bought shares of Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX). In a filing disclosed on April 07th, the Representative disclosed that they had bought between $1,001 and $15,000 in Crinetics Pharmaceuticals stock on March 3rd.

Representative Gilbert Ray Cisneros, Jr. also recently made the following trade(s):

• Sold $1,001 – $15,000 in shares of MACOM Technology Solutions (NASDAQ:MTSI) on 3/27/2026.
• Purchased $1,001 – $15,000 in shares of StandardAero (NYSE:SARO) on 3/27/2026.
• Purchased $1,001 – $15,000 in shares of FirstService (NASDAQ:FSV) on 3/27/2026.
• Sold $1,001 – $15,000 in shares of Charles Schwab (NYSE:SCHW) on 3/27/2026.
• Sold $1,001 – $15,000 in shares of Advanced Energy Industries (NASDAQ:AEIS) on 3/27/2026.
• Sold $1,001 – $15,000 in shares of Flex (NASDAQ:FLEX) on 3/27/2026.
• Purchased $1,001 – $15,000 in shares of LPL Financial (NASDAQ:LPLA) on 3/27/2026.
• Purchased $1,001 – $15,000 in shares of DoorDash (NASDAQ:DASH) on 3/27/2026.
• Sold $1,001 – $15,000 in shares of Viavi Solutions (NASDAQ:VIAV) on 3/27/2026.
• Purchased $15,001 – $50,000 in shares of Fabrinet (NYSE:FN) on 3/27/2026.

Crinetics Pharmaceuticals Trading Down 0.5%

Shares of CRNX traded down $0.19 during midday trading on Thursday, reaching $39.77. The stock had a trading volume of 376,167 shares, compared to its average volume of 1,264,818. The firm has a 50 day simple moving average of $40.80 and a 200-day simple moving average of $44.14. Crinetics Pharmaceuticals, Inc. has a one year low of $25.38 and a one year high of $57.99. The firm has a market cap of $4.16 billion, a PE ratio of -8.05 and a beta of 0.30.

Crinetics Pharmaceuticals (NASDAQ:CRNX) last released its quarterly earnings data on Thursday, February 26th. The company reported ($1.29) earnings per share for the quarter, topping the consensus estimate of ($1.37) by $0.08. Crinetics Pharmaceuticals had a negative net margin of 6,046.22% and a negative return on equity of 41.46%. The company had revenue of $6.16 million for the quarter, compared to analyst estimates of $4.32 million. During the same period in the previous year, the business earned ($0.88) EPS. Crinetics Pharmaceuticals’s revenue for the quarter was up NaN% compared to the same quarter last year. As a group, research analysts forecast that Crinetics Pharmaceuticals, Inc. will post -3.73 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of CRNX. Wellington Management Group LLP grew its stake in Crinetics Pharmaceuticals by 44.3% during the third quarter. Wellington Management Group LLP now owns 8,381,991 shares of the company’s stock worth $349,110,000 after buying an additional 2,574,683 shares in the last quarter. Farallon Capital Management LLC raised its position in shares of Crinetics Pharmaceuticals by 20.2% in the 4th quarter. Farallon Capital Management LLC now owns 6,933,098 shares of the company’s stock valued at $322,736,000 after buying an additional 1,163,000 shares in the last quarter. Janus Henderson Group PLC lifted its holdings in shares of Crinetics Pharmaceuticals by 15.1% during the 4th quarter. Janus Henderson Group PLC now owns 4,440,691 shares of the company’s stock worth $206,604,000 after acquiring an additional 581,900 shares during the period. Paradigm Biocapital Advisors LP lifted its holdings in shares of Crinetics Pharmaceuticals by 8.8% during the 3rd quarter. Paradigm Biocapital Advisors LP now owns 2,550,774 shares of the company’s stock worth $106,240,000 after acquiring an additional 207,221 shares during the period. Finally, Baker BROS. Advisors LP boosted its position in shares of Crinetics Pharmaceuticals by 488.9% during the 4th quarter. Baker BROS. Advisors LP now owns 1,648,869 shares of the company’s stock worth $76,755,000 after acquiring an additional 1,368,869 shares in the last quarter. Institutional investors and hedge funds own 98.51% of the company’s stock.

Insiders Place Their Bets

In other Crinetics Pharmaceuticals news, CFO Tobin Schilke sold 6,713 shares of the firm’s stock in a transaction on Tuesday, March 3rd. The stock was sold at an average price of $39.67, for a total value of $266,304.71. Following the sale, the chief financial officer owned 78,121 shares of the company’s stock, valued at approximately $3,099,060.07. This trade represents a 7.91% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, Director Coelho Rogerio Vivaldi sold 5,000 shares of Crinetics Pharmaceuticals stock in a transaction on Thursday, March 12th. The shares were sold at an average price of $36.15, for a total value of $180,750.00. Following the completion of the transaction, the director owned 16,300 shares in the company, valued at approximately $589,245. The trade was a 23.47% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 57,217 shares of company stock valued at $2,154,439 over the last three months. 4.60% of the stock is owned by corporate insiders.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently weighed in on CRNX shares. The Goldman Sachs Group raised Crinetics Pharmaceuticals from a “neutral” rating to a “buy” rating and set a $67.00 target price for the company in a report on Monday, January 12th. Wall Street Zen lowered shares of Crinetics Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Saturday, March 28th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Crinetics Pharmaceuticals in a research note on Wednesday, January 21st. Lifesci Capital raised shares of Crinetics Pharmaceuticals to a “strong-buy” rating in a report on Friday, February 13th. Finally, Citizens Jmp lowered their target price on shares of Crinetics Pharmaceuticals from $105.00 to $96.00 and set a “market outperform” rating on the stock in a report on Monday, March 2nd. One equities research analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, Crinetics Pharmaceuticals presently has an average rating of “Moderate Buy” and an average price target of $76.63.

About Representative Cisneros

Gil Cisneros (Democratic Party) is a member of the U.S. House, representing California’s 31st Congressional District. He assumed office on January 3, 2025. His current term ends on January 3, 2027.

Cisneros (Democratic Party) is running for re-election to the U.S. House to represent California’s 31st Congressional District. He declared candidacy for the 2026 election.

Gil Cisneros served in the U.S. Navy as a supply officer from 1994 to 2004. Cisneros earned a bachelor’s degree in political science from George Washington University in 1994, a master’s in business administration from Regis University in 2002, and a master’s degree in urban education policy from Brown University in 2015. His career experience includes working as a logistics manager for Frito-Lay. In 2010, Cisneros won the lottery and became involved in activism and philanthropy, founding a scholarship program for local high school students. In 2021, President Joe Biden (D) appointed Cisneros as under secretary of defense for personnel and readiness.

Crinetics Pharmaceuticals Company Profile

Crinetics Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for rare endocrine diseases. The company’s proprietary platform leverages insights into hormone receptor signaling to design small-molecule candidates that address conditions driven by dysregulated hormone activity. Crinetics’ research efforts center on targeting somatostatin, vasopressin and other GPCR-mediated pathways with orally bioavailable molecules intended to improve patient convenience and adherence.

The company’s lead product candidate, paltusotine (formerly CRN04777), is a selective, non-peptide somatostatin receptor type 2 agonist being evaluated for the treatment of acromegaly and carcinoid syndrome diarrhea.